How Do I Lower My Lp(a) Cholesterol?

Lipoprotein(a), or Lp(a), is one of the most important and most overlooked cardiovascular risk factors. Unlike standard LDL cholesterol, Lp(a) levels are primarily determined by genetics, which means diet and exercise have minimal direct effect on the number itself. However, this does not mean you are powerless. While significantly lowering Lp(a) is difficult with current approaches, the real opportunity lies in reducing the risk that elevated Lp(a) creates. By aggressively addressing inflammation, optimizing other lipid markers, supporting vascular health, and reducing all modifiable cardiovascular risk factors, you can substantially lower your overall risk even if your Lp(a) number remains elevated. The goal shifts from lowering Lp(a) directly to protecting your arteries from the damage it can cause.

Understanding Lp(a) And Why It Matters

Lipoprotein(a) is a type of LDL particle with an additional protein called apolipoprotein(a) attached to it. This protein makes Lp(a) particles stickier and more prone to accumulating in artery walls. Lp(a) also has properties that promote blood clotting and inflammation, compounding its cardiovascular risk. Elevated Lp(a) is an independent risk factor for heart disease, stroke, and aortic valve disease, meaning it increases risk regardless of what your other cholesterol numbers look like.

The challenge with Lp(a) is that it behaves differently from other lipoproteins. Your liver produces Lp(a) at a rate largely determined by the genes you inherited. Unlike LDL, which responds readily to diet, exercise, and medications, Lp(a) production is relatively fixed. This genetic determination is why two people can follow identical lifestyles and have dramatically different Lp(a) levels.

Most people do not know their Lp(a) level because it is not included in standard lipid panels. This is a significant gap in conventional cardiovascular screening. Approximately 20% of the population has elevated Lp(a), making it one of the most common inherited risk factors for heart disease. If you have a family history of early heart disease, stroke, or aortic valve problems, testing Lp(a) is particularly important.

What Can Actually Lower Lp(a)

Honest assessment of current options is important. Very few interventions reliably lower Lp(a), and those that do often have modest effects or significant trade-offs.

Niacin (Vitamin B3): High-dose niacin can reduce Lp(a) by 20-30% in some people. However, niacin has side effects including flushing, liver stress, and potential blood sugar elevation. Clinical trials have also shown that niacin’s Lp(a) reduction does not necessarily translate to reduced cardiovascular events, raising questions about its clinical benefit. Niacin should only be used under medical supervision with appropriate monitoring.

PCSK9 Inhibitors: These injectable medications, originally developed for LDL reduction, also lower Lp(a) by approximately 20-30%. They are typically reserved for high-risk patients who cannot achieve adequate LDL control with other medications. The Lp(a) reduction is a beneficial secondary effect rather than the primary indication.

Lipoprotein Apheresis: This is a procedure similar to dialysis that physically removes Lp(a) from the blood. It can reduce levels by 60-70% immediately after treatment, but levels rebound within two weeks, requiring regular sessions. Apheresis is generally reserved for people with very high Lp(a) and progressive cardiovascular disease despite maximal other therapies.

Emerging Therapies: Antisense oligonucleotides (ASO) and small interfering RNA (siRNA) therapies that target Lp(a) production in the liver are currently in advanced clinical trials. These therapies can reduce Lp(a) by 80% or more and represent the most promising future treatment option. If trials succeed, these medications may become available within the next few years.

Hormone Considerations: Estrogen can lower Lp(a), which partly explains why Lp(a) levels often rise in women after menopause. Testosterone may also have modest effects. Hormone therapy decisions should be made based on the full clinical picture, not solely to address Lp(a), but this effect may be relevant for some patients considering hormone optimization for other reasons.

The More Important Strategy: Reducing The Risk Lp(a) Creates

Since directly lowering Lp(a) is difficult with current tools, the more practical and immediately actionable approach is reducing the harm that elevated Lp(a) can cause. Lp(a) does not damage arteries in isolation. It acts in concert with inflammation, oxidative stress, and other lipoproteins. By optimizing these other factors, you can significantly reduce your overall cardiovascular risk even if your Lp(a) number remains elevated.

Aspirin: The 2026 ACC/AHA guideline notes that post hoc analyses from 2 primary prevention trials found aspirin reduced cardiovascular events in individuals with high Lp(a). The ASPREE trial analysis found that in the highest LPA genetic risk quintile, aspirin reduced MACE by 3.3 events per 1,000 person-years without significantly increased bleeding. A 2025 review describes growing evidence for ~50% reduction in coronary events and ASCVD mortality with aspirin in individuals with Lp(a) >50 mg/dL.

Aggressively Address Inflammation: Inflammation is what allows Lp(a) to enter and damage artery walls. When the endothelium is inflamed and dysfunctional, it becomes permeable to lipoproteins including Lp(a). By reducing chronic inflammation through diet, gut health optimization, removal of inflammatory triggers, and addressing metabolic dysfunction, you make your arteries more resistant to Lp(a)-mediated damage. Testing inflammatory markers like hs-CRP, Lp-PLA2, and oxidized LDL provides insight into your inflammatory status.

Optimize Other Lipid Markers: If you cannot change your Lp(a), ensure everything else is optimized. This means achieving ideal LDL particle number and size, optimal HDL function, low triglycerides, and healthy ApoB levels. Advanced lipid testing provides a complete picture of your lipoprotein status beyond basic cholesterol numbers. Reducing other atherogenic particles reduces the total burden on your arteries.

Support Endothelial Health: The endothelium is your first line of defense against atherosclerosis. Healthy endothelium produces nitric oxide, which keeps vessels flexible, prevents clotting, and creates a barrier against lipoprotein infiltration. Supporting endothelial function through exercise, nitrate-rich vegetables, adequate sleep, stress management, and targeted nutrients helps protect your arteries from Lp(a)-mediated damage.

Address Insulin Resistance: Insulin resistance promotes inflammation, oxidative stress, and endothelial dysfunction, all of which amplify the damage Lp(a) can cause. Improving insulin sensitivity through dietary changes, movement, sleep, and stress management creates a metabolic environment less conducive to atherosclerosis progression.

Reduce Oxidative Stress: Oxidized lipoproteins are more atherogenic than non-oxidized ones. Supporting your body’s antioxidant systems through nutrient-dense foods, adequate intake of vitamins C and E, polyphenols from colorful plants, and reducing exposure to oxidative stressors helps protect lipoproteins from oxidation.

Eliminate Other Risk Factors: If you have elevated Lp(a), you cannot afford to carry other modifiable risk factors. Blood pressure should be optimized. Blood sugar should be well controlled. Smoking must be eliminated. Body composition should be addressed. Every additional risk factor multiplies the danger from elevated Lp(a).

What You Should Consider

Get Tested: Lp(a) only needs to be measured once since levels are genetically determined and remain relatively stable throughout life. If you have not been tested, especially if you have family history of early cardiovascular disease, request this test. It is not included in standard panels but is readily available.

Understand Your Total Risk Picture: Elevated Lp(a) is one risk factor among many. Comprehensive testing that includes advanced lipid analysis, inflammatory markers, metabolic markers, and vascular imaging provides context for how much your Lp(a) is actually contributing to your personal risk.

Do Not Rely On Standard Approaches: Statins do not lower Lp(a). Standard dietary advice for cholesterol does not significantly affect Lp(a). If elevated Lp(a) is your primary concern, you need a targeted strategy, not generic cardiovascular recommendations.

Focus On What You Can Control: While you may not be able to change your Lp(a) level significantly, you have substantial control over inflammation, metabolic health, other lipid markers, blood pressure, and lifestyle factors. Maximizing these controllable factors is your most powerful protection.

Consider Family Implications: Because Lp(a) is genetic, elevated levels in you suggest your first-degree relatives may also be affected. Encouraging family members to get tested allows for early intervention before cardiovascular disease develops.

Stay Informed About Emerging Therapies: Treatments specifically targeting Lp(a) are advancing through clinical trials. If you have significantly elevated Lp(a), staying connected with a knowledgeable practitioner ensures you can access new options as they become available.

When To Seek Care Urgently

Talk it through with our team

If you have elevated Lp(a) or have not been tested, a comprehensive cardiovascular evaluation can determine your Lp(a) level, assess your total risk picture including inflammation and advanced lipid markers, and develop a personalized strategy to protect your cardiovascular health despite this genetic risk factor.

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026. doi:10.1016/j.jacc.2025.11.016.
2. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. doi:10.1161/ATV.0000000000000147.
3. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361.
4. Nordestgaard BG, Langsted A. Lipoprotein(a) and Cardiovascular Disease. Lancet. 2024;404(10459):1255-1264. doi:10.1016/S0140-6736(24)01308-4.
5. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin Therapy Increases Lipoprotein(a) Levels. European Heart Journal. 2020;41(24):2275-2284. doi:10.1093/eurheartj/ehz310.